Loading...
XASX
CMP
Market cap30mUSD
Jul 10, Last price  
0.23AUD
1D
4.55%
1Q
-17.86%
Jan 2017
-73.56%
IPO
-74.16%
Name

Compumedics Ltd

Chart & Performance

D1W1MN
XASX:CMP chart
P/E
P/S
0.90
EPS
Div Yield, %
Shrs. gr., 5y
0.51%
Rev. gr., 5y
7.79%
Revenues
51m
+2.66%
38,877,00036,871,00038,582,00038,181,00032,611,00031,265,00027,915,00027,150,00029,068,00033,495,00037,544,00034,417,00037,002,00041,505,00035,069,00035,740,00037,756,00042,408,00049,719,00051,040,000
Net income
-1m
L+276.33%
-1,595,000123,000756,0002,727,000414,00081,000-2,829,000-1,489,000909,0001,970,0003,273,0001,305,0002,784,0004,016,000-5,838,000998,0001,357,000-6,122,000-338,000-1,272,000
CFO
681k
-65.97%
-1,378,000847,0001,863,0004,568,000454,000-263,0001,376,000409,000686,0002,202,0002,232,000864,000559,0005,136,0005,383,0001,324,0003,287,00048,9992,001,000681,000
Dividend
Nov 22, 20040.005 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
IPO date
Dec 21, 2000
Employees
135
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT